Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARγ signalling pathway
- 31 March 2022
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 45 (2) , 275-291
Abstract
Background Cholangiocarcinoma is a devastating cancer with a poor prognosis. Previous reports have presented conflicting results on the role of transforming growth factor-β-induced protein (TGFBI) in malignant cancers. Currently, our understanding of the role of TGFBI in cholangiocarcinoma is ambiguous. The aim of the present study was to investigate the role of TGFBI in human cholangiocarcinoma. Methods Iterative patient partitioning (IPP) scoring and consecutive elimination methods were used to select prognostic biomarkers. mRNA and protein expression levels were determined using Gene Expression Omnibus (GEO), Western blot and ELISA analyses. Biological activities of selected biomarkers were examined using both in vitro and in vivo assays. Prognostic values were assessed using Kaplan–Meier and Liptak’s z score analyses. Results TGFBI was selected as a candidate cholangiocarcinoma biomarker. GEO database analysis revealed significantly higher TGFBI mRNA expression levels in cholangiocarcinoma tissues compared to matched normal tissues. TGFBI protein was specifically detected in a soluble form in vitro and in vivo. TGFBI silencing evoked significant anti-cancer effects in vitro. Soluble TGFBI treatment aggravated the malignancy of cholangiocarcinoma cells both in vitro and in vivo through activation of the integrin beta-1 (ITGB1) dependent PPARγ signalling pathway. High TGFBI expression was associated with a poor prognosis in patients with cholangiocarcinoma. Conclusions Our data suggest that TGFBI may serve as a promising prognostic biomarker and therapeutic target for cholangiocarcinoma.Keywords
Funding Information
- Ministry of Education (2016R1A6A1A03012862)
This publication has 47 references indexed in Scilit:
- Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic CancerPPAR Research, 2012
- β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cellsMolecular Cancer, 2012
- TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cellsCancer Letters, 2011
- Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesBritish Journal of Pharmacology, 2011
- Integrin α1β1 Regulates Epidermal Growth Factor Receptor Activation by Controlling Peroxisome Proliferator-Activated Receptor γ-Dependent Caveolin-1 ExpressionMolecular and Cellular Biology, 2010
- Inhibition of Human Scleral Fibroblast Cell Attachment to Collagen Type I by TGFBIpInvestigative Ophthalmology & Visual Science, 2009
- PPARγ and Apoptosis in CancerPPAR Research, 2008
- The Role of PPARs in CancerPPAR Research, 2008
- The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to PaclitaxelCancer Cell, 2007
- Cholangiocarcinoma: Modern advances in understanding a deadly old diseaseJournal of Hepatology, 2006